Kinlytic^™

Our commercially available product urokinase for injection, marketed as Kinlytic, is a thrombolytic drug. Urokinase is a natural human protein primarily produced in the kidneys that stimulates the body's natural clot-dissolving processes. According to the FDA, approximately 600,000 people in the U.S. every year experience a blood clot that lodges in the lungs, known as a pulmonary embolism. A portion of these are classified as acute massive pulmonary emboli, meaning that they involve obstruction of blood flow to a lobe or multiple segments of the lungs. Acute massive pulmonary emboli, which result in nearly 60,000 deaths in the U.S. annually, must be treated quickly, as most of these deaths occur within 30 to 60 minutes after the onset of symptoms. Kinlytic is FDA approved and marketed for the treatment of acute massive pulmonary embolism.

Urokinase has been administered to over four million patients since its approval, and we estimate that approximately 700 acute care hospitals in the U.S. include urokinase on their pharmacy formulary today.

Begining in April 2008, Abbokinase® (urokinase) has been renamed Kinlytic™(urokinase for injection). The only changes are to the proprietary name and NDC number. For information please vist Kinlytic.com.